Analysts Anticipate Gamida Cell Ltd (GMDA) to Announce ($0.71) EPS

Shares of Gamida Cell Ltd (NASDAQ:GMDA) have been assigned a consensus broker rating score of 1.50 (Buy) from the two analysts that provide coverage for the company, Zacks Investment Research reports. One research analyst has rated the stock with a buy recommendation and one has given a strong buy recommendation to the company.

Analysts have set a 12-month consensus price objective of $17.50 for the company and are forecasting that the company will post ($0.71) EPS for the current quarter, according to Zacks. Zacks has also assigned Gamida Cell an industry rank of 75 out of 257 based on the ratings given to its competitors.

Several equities analysts recently issued reports on GMDA shares. CIBC started coverage on Gamida Cell in a research report on Wednesday, November 21st. They set an “outperform” rating and a $15.00 price target on the stock. Royal Bank of Canada started coverage on Gamida Cell in a research report on Tuesday, November 20th. They set an “outperform” rating and a $20.00 price target on the stock. BMO Capital Markets started coverage on Gamida Cell in a research report on Wednesday, November 21st. They set a “buy” rating and a $19.00 price target on the stock. Oppenheimer started coverage on Gamida Cell in a research report on Wednesday, November 21st. They set an “outperform” rating and a $15.00 price target on the stock. Finally, Needham & Company LLC started coverage on Gamida Cell in a research report on Monday. They set a “buy” rating and a $23.00 price target on the stock.

GMDA traded down $1.50 on Wednesday, hitting $13.40. 3,717 shares of the company were exchanged, compared to its average volume of 46,353. Gamida Cell has a 12 month low of $7.99 and a 12 month high of $15.39.

Gamida Cell Company Profile

Gamida Cell Ltd., a clinical stage biopharmaceutical company, focuses on developing cell therapies to cure cancer, and rare and serious hematologic diseases in the United States, the European Union, and internationally. The company's lead product candidate is NiCord, a nicotinamide (NAM)-expanded cord blood cell therapy that is in Phase 3 clinical trials for use as a curative stem cell graft for patients in hematopoietic stem cell transplant.

Featured Story: Asset Allocation and Your Retirement

Get a free copy of the Zacks research report on Gamida Cell (GMDA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Gamida Cell (NASDAQ:GMDA)

Receive News & Ratings for Gamida Cell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gamida Cell and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply